Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 35 Carboplatin 24 Specimen Handling 20 Cyclophosphamide 19 Magnetic Resonance Spectroscopy 18 fludarabine 15 Dexamethasone 15 Nivolumab 14 Gemcitabine 14 Bevacizumab 14 Biopsy 12 atezolizumab 11 Temozolomide 11 Paclitaxel 10 Docetaxel 10 Cisplatin 10 venetoclax 9 Rituximab 9 Pemetrexed 9 Ipilimumab 9 Prednisone 8 Lenalidomide 8 Fluorouracil 8 blinatumomab 7 Vincristine 7 Radiotherapy 7 Oxaliplatin 7 Capecitabine 7 olaparib 6 lenvatinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × capmatinib × 30 days × Clear all

NCT05488314 2026-06-05

METalmark

Janssen Research & Development, LLC

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡